PeptiDream Inc., a public Tokyo-based biopharmaceutical company (PeptiDream) (TOKYO:4587) announced today, the appointment of Dr. Keiichi Masuya as Chief Operating Officer (COO).
Dr. Masuya has had a distinguished scientific career, most recently serving as “Novartis Leading Scientist” at Novartis in Basel, Switzerland. Dr. Masuya has worked for Novartis for the past 14 years, 10 of those years in Basel, Switzerland and 4 years at the Novartis Institutes for Biomedical Research in Tsukuba, Japan. Dr. Masuya led the project team through the discovery and development of Zykadia (ceritnib, LDK378) for the treatment of non-small cell lung cancer (NSCLC), which received FDA Breakthrough Therapy designation in 2013 and was approved in early 2014. He also led the project team in the discovery and development of CGM097, for the treatment of advanced solid tumors, which is currently in Phase I testing. Dr. Masuya is a leading expert in the field of PPI inhibitors (protein-protein interaction inhibitors), and has an exceptional track record of discovering and bringing lead candidates into clinical development.
Help employers find you! Check out all the jobs and post your resume.
